Comparison of diabetic retinopathy severity grading on ETDRS 7-field versus ultrawide-field assessment

Competing interests

YA, MGN, SBV (None), CR: Eyenuk, Inc. (E), SB: Eyenuk, Inc. (E), KS: Eyenuk, Inc. (E), CJ (None), NC: Abbvie (C,S) Apellis ©, Bayer (C,S,R), Novartis (C), Bausch & Lomb (C), Alcon (C), Optos PLC (S,C,R), Topcon (S,C,R), Hoffman La Roche (C), SriniVas R Sadda: Amgen (C), Allergan (C), Genentech/Roche (C), Iveric (C), Oxurion (C), Novartis (C), Regeneron (C), Bayer (C), 4DMT (C), Centervue (C,R), Heidelberg (C,R), Optos (C,R), Merck (C), Apellis (C), Astellas (C), Carl Zeiss Meditec (R), Nidek (R), Topcon (R). The authors declare no competing interests.

留言 (0)

沒有登入
gif